At the news
? BULLISHIMPACT 7/10 INSIDER-BUY filed Jun 16, 2026 at 18:08 ET
RA Capital Management, a director and 10% owner, purchased 1.43 million shares of Artiva Biotherapeutics for $11.14 million across five open-market trades from June 9-12, 2026. The purchase represents approximately 4.9% of the company's $227 million market cap, a highly material insider buying signal that indicates strong conviction in the company's prospects.
- Total insider purchase of $11.14 million over 5 trades from June 9-12, 2026
- Purchase represents ~4.9% of $227M market cap, well above the 2% materiality threshold
- Only insider is RA Capital Management, L.P., acting as both director and 10% owner
- Prices ranged from $6.91 to $8.99 per share, with largest trades at higher prices
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access